Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 1510 participants.
Also called NCT02664649
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,510 participants
- Registry
-
NCT02664649 -
2015-001676-21
-
- Other papers using this trial's data
- Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial Substudy
- Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France, Germany, Italy, Spain
- Registry status
- Completed
Technical summary
Registry record NCT02664649. Randomized; no masking; primary purpose treatment. Start 2016-08-26 (actual); primary completion 2020-10-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis
- Acronym
- ATLANTIS
- Condition
- Symptomatic Aortic Stenosis
- Condition
- Eligible for Transcatheter Aortic Valve Replacement
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Standard of care
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborator
- Action Research Group
- Collaborator
- Bristol-Meyers Squibb & Pfizer
Record details
- Record id
cardio:ct-nct02664649- Content hash
3951a54c969008c45a1cd89aebfcd4b01940d928f301148ecfaced4cdbb41668